Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

The FDA said it wants suicide warnings to be taken off some popular weight-loss medications following a comprehensive safety ...

Pharmaceutical companies are paying thousands of Indiana doctors to talk about GLP-1 drugs, a WRTV Investigation has ...

Strive Compounding Pharmacy sues Eli Lilly and Novo Nordisk over alleged GLP-1 weight loss drug competition limits. Read more ...

The rising popularity of weight loss drugs is a key reason healthcare company Eli Lilly ( LLY 1.31%) has been soaring in ...

Momentum in weight-loss drugs is the main reason why Eli Lilly's stock soared in 2025. Over the last five years it is up 459%, and that is excluding dividends. It is the largest drugmaker in the world ...

The request comes after a two-year review into reported links between GLP-1RAs and psychiatric adverse events.

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation ...

After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely ...

Eli Lilly is aware of this fact, which helps explain why it acquired Adverum Biotechnologies in late 2025 and just agreed to ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.